Brief: Arcutis Submits SNDA For Zoryve Cream For Treatment Of Plaque Psoriasis In Children
03/09/2025 16:53
Sept 3 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O: ARCUTIS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION FOR ZORYVE® (ROFLUMILAST) CREAM 0.3% TO EXPAND INDICATION FOR TREATMENT OF PLAQUE PSORIASIS IN CHILDREN AGES 2 TO 5 Source text: ID:nGNX1zr2VW Further company coverage: ARQT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Canada Przoryve Cream 0.05% Receives Health Canada Approval For Atopic Dermatitis
Arcutis Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlook
Arcutis Biotherapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview
Brief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4